T2 Biosystems (TTOO) said Monday it extended its multiyear capital equipment supplier agreement with Vizient until March 31, 2026.

The contract covers products such as the T2Dx instrument, the T2Bacteria panel and the T2Candida panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood, the company said.

T2 Biosystems shares were up 3.6% in recent trading.

Price: 0.38, Change: +0.01, Percent Change: +3.56